Evaluation of Myogenin and MyoD1 as Immunohistochemical Markers of Canine Rhabdomyosarcoma.
Evaluation of Myogenin and MyoD1 as Immunohistochemical Markers of Canine Rhabdomyosarcoma.
复制标题
DOI：
10.1177/0300985820988146
复制
发表时间：
2021-05
影响因子：
2.4
通讯作者：
Seguin B
中科院分区：
文献类型：
--
作者：
Tuohy JL;Byer BJ;Royer S;Keller C;Nagai-Singer MA;Regan DP;Seguin B
犬横纹肌肉瘤（RMS）提出了一个诊断挑战，由于其重叠的组织学特征与其他软组织肉瘤。RMS的诊断目前依赖于免疫组化（IHC）阳性的desmin标记；然而，在非rms肿瘤中也观察到desmin的表达。据报道，Myogenin和MyoD1是人RMS敏感和特异性的免疫结构标记物，但它们在兽医肿瘤学中应用并不广泛。本研究的目的是制定肌原素和MyoD1的免疫组化方案，评估犬RMS中肌原素和MyoD1的标记，并报告临床结果。回顾性评价16例可能的RMS。13例根据组织学特征及肌原素、MyoD1免疫标记诊断为RMS， 2例辅以电镜检查。3例RMS患者Desmin阴性。2例为硬化型。RMS犬的中位年龄为7.2岁。解剖肿瘤的位置包括先前报道的膀胱、喉部、心脏和眼眶，以及其他软组织肉瘤的典型位置。5只狗的生存期为47 ~ 1480天。本研究表明，MyoD1和肌原素应与desmin一起作为犬RMS的IHC诊断组的一部分。利用这些抗体来提高犬RMS诊断的准确性，将最终允许更好地表征该疾病的生物学行为和临床结果，为犬RMS的未来比较研究奠定基础。
Canine rhabdomyosarcoma (RMS) presents a diagnostic challenge due to its overlapping histologic features with other soft tissue sarcomas. The diagnosis of RMS currently relies on positive immunohistochemical (IHC) labeling for desmin; however, desmin expression is also observed in non-RMS tumors. Myogenin and MyoD1 are transcription factors reported to be sensitive and specific IHC markers for human RMS, but they are not widely used in veterinary oncology. The goals of this study were to develop an IHC protocol for myogenin and MyoD1, evaluate myogenin and MyoD1 labeling in canine RMS, and report clinical outcomes. Sixteen cases of possible RMS were retrospectively evaluated. A diagnosis of RMS was confirmed in 13 cases based on histological features and immunolabeling for myogenin and MyoD1, with the aid of electron microscopy in 2 cases. Desmin was negative in 3 cases of RMS. Two cases were of the sclerosing variant. The median age of dogs with RMS was 7.2 years. Anatomic tumor locations included previously reported sites such as bladder, larynx, heart, and orbit, as well as other locations typical of soft tissue sarcomas. Survival ranged from 47 to 1480 days for 5 dogs with available data. This study demonstrated that MyoD1 and myogenin should be included with desmin as part of a diagnostic IHC panel for canine RMS. Utilization of these antibodies to improve the accuracy of canine RMS diagnosis will ultimately allow for better characterization of the biological behavior and clinical outcomes of this disease, providing the groundwork for future comparative investigations in canine RMS.
登录
查看更多内容
影响因子：
4.5
作者：
Jo, Vickie Y.;Fletcher, Christopher D. M.
通讯作者：
Fletcher, Christopher D. M.
影响因子：
2.4
作者：
LaDouceur, Elise E. B.;Stevens, Sarah E.;Reilly, Christopher M.
通讯作者：
Reilly, Christopher M.
影响因子：
1.2
作者：
Murakami, Mami;Sakai, Hiroki;Masegi, Toshiaki
通讯作者：
Masegi, Toshiaki
影响因子：
6.4
作者：
CARTER, RL;MCCARTHY, KP;PINKERTON, CR
通讯作者：
PINKERTON, CR
影响因子：
2.4
作者：
LaRock, RG;Ginn, PE
通讯作者：
Ginn, PE